XML 35 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Discontinued Operations
 3 Months Ended
Mar. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued Operations Discontinued Operations
Disbanding of Regenerative Medicine Business Unit
On June 20, 2023, the Company announced the disbanding of its Regenerative Medicine business unit and the suspension of its Knee Osteoarthritis clinical trial program. During the fourth quarter of 2023, the Company materially completed the regulatory obligations associated with the clinical trial.
Financial Statement Impact of Discontinued Operations
The income and expenses of the discontinued operation have been classified as income (loss) from discontinued operations in the consolidated statements of operations for the three months ended March 31, 2024 and 2023 as follows (in thousands):
Three Months Ended March 31,
20242023
Selling, general and administrative expense
— 29 
Research and development expense
$(200)3,012 
Income (loss) from discontinued operations
$200 $(3,041)